经验

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

September 3, 2025

Cooley advised Argo Biopharma, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, on its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo’s pipeline.

Read more

Related contacts

Lila Hope
Partner, 帕罗奥图
Jennifer Raab
Partner, 帕罗奥图
叶明晖
律师
Yuhan Wu
Associate, 帕罗奥图
Aaron Pomeroy
Partner, 科罗拉多
Amanda Pacheco
Associate, 帕罗奥图
Julia R. Brinton
Special Counsel, 华盛顿特区
David Burns
Special Counsel, 华盛顿特区
Andrew Epstein
Special Counsel, Seattle
Mari Dugas
Associate, 华盛顿特区
刘毅铭
上海办事处主管合伙人, 上海
陆培祥
合伙人, 新加坡
Phil Mitchell
Partner, 纽约
王滨
资深顾问, 帕罗奥图

Related Practices & Industries

Akeso Announces HK$3.97 Billion Placement of Shares

August 28, 2025

Cooley advised Akeso (Hong Kong Stock Exchange: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$3.97 billion (US$509.01 million) placement of shares.

Read more

Related contacts

刘毅铭
上海办事处主管合伙人, 上海
余仙
香港办事处主管合伙人, 香港
王一盈
顾问律师, 上海
刘颖
律师, 香港
王峥
律师, 香港

Related Practices & Industries

Innogen Pharmaceutical Announces HK$682.87 Million IPO

August 15, 2025

Cooley advised Innogen Pharmaceutical on its HK$682.87 million initial public offering (IPO).

Read more

Related contacts

金朝
合伙人, 上海
刘毅铭
上海办事处主管合伙人, 上海
武梦超
律师, 北京
李涵
注册外国律师(纽约), 香港
徐云翔
律师, 上海

Related Practices & Industries

Leads Biolabs Announces HK$1.29 Billion IPO

July 25, 2025

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Read more

Related contacts

余仙
香港办事处主管合伙人, 香港
刘毅铭
上海办事处主管合伙人, 上海
杨凯婷
顾问律师, 香港
王一盈
顾问律师, 上海
徐云翔
律师, 上海
刘学谦
律师, 香港
吴茜
律师, 上海
Daniel Zheng
Associate, 上海
李正洋
国际法律项目经理, 香港
Cindy Pan
International Legal Project Manager, 香港
Zoe Wang
International Legal Project Manager, 上海
Francis Wheeler
Senior Counsel, 科罗拉多
Mark Windfeld-Hansen
Senior Counsel, 帕罗奥图
Vince Sampson
Special Counsel, 华盛顿特区
Karen Tsai
Special Counsel, 华盛顿特区

Related Practices & Industries

DualityBio Announces HK$1.64 Billion IPO

April 24, 2025

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Read more

Related contacts

刘毅铭
上海办事处主管合伙人, 上海
余仙
香港办事处主管合伙人, 香港
Vince Sampson
Special Counsel, 华盛顿特区
Karen Tsai
Special Counsel, 华盛顿特区
徐璨
顾问律师, 上海
李涵
注册外国律师(纽约), 香港
刘孜翔
律师, 上海
Patrick Sharma
Associate, 洛杉矶
王一盈
顾问律师, 上海
徐云翔
律师, 上海
杨凯婷
顾问律师, 香港
于子程
Associate, 香港
于子程
Associate, 香港
魏 乐天
法律顾问, 上海
Cindy Pan
International Legal Project Manager, 香港
Zoe Wang
International Legal Project Manager, 上海
Philip Kwan
Senior Legal Assistant, 香港

Related Practices & Industries

查看全部

荣誉与排名

汤森路透《亚洲法律杂志》(Asian Legal Business)
“亚洲交易律师”
(2024年)

《商法》“The A-List法律精英”
外资律所“律界精锐”
(2023-2025年)

《法律500强》亚太榜单(The Legal 500 Asia Pacific)
“中国生命科学与医疗健康业务(国际律所):领先合伙人”
(2025年) 

钱伯斯大中华区法律指南
“中国生命科学业务(国际律所):新锐律师”
(2025年)

《国际金融法律评论》(IFLR1000) 亚太榜单
“中国资本市场、并购、私募股权业务(国际律所):卓越律师”
(2024年)

汤森路透《亚洲法律杂志》(Asian Legal Business)
“2022 ALB China十五佳资本市场律师”
(2022年)

汤森路透《亚洲法律杂志》(Asian Legal Business)
“2022 ALB China十五佳律师新星”
(2022年)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.